Skip to main content
. 2020 Feb 10;10:2262. doi: 10.1038/s41598-020-59057-5

Figure 2.

Figure 2

The prognostic value of the expression of SETD3 in patients with breast cancer stratified by hormone receptor status. Kaplan-Meier relapse-free survival curves are plotted based on: (A) all breast cancer patients (n = 3951), (B) Estrogen receptor (ER) positive status, ER+ (n = 3,082) (C) Progesterone receptor negative (PR) status, PR- (n = 549), and (D) triple-negative expression of ER, PR, and Her2 (n = 196). Log-rank p values and hazard ratios (HRs; 95% confidence interval in parentheses) are shown. The corresponding Affymetrix IDs is: 212465_at_SETD3.